9 Meters Biopharma, Inc. (NMTR)
$0.2249
Rating:
Recommendation:
-
| Symbol | NMTR |
|---|---|
| Price | $0.2249 |
| Beta | 0.343 |
| Volume Avg. | 3.11M |
| Market Cap | 58.273M |
| Shares () | - |
| 52 Week Range | 0.221-1.46 |
| 1y Target Est | - |
| DCF Unlevered | NMTR DCF -> | |
|---|---|---|
| DCF Levered | NMTR LDCF -> | |
| ROE | -94.39% | Strong Sell |
| ROA | -108.75% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 26.90% | Neutral |
| P/E | - | |
| P/B | 1.88 | Strong Buy |
Latest NMTR news
About
Download (Excel)9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.